Montelukast: Its role in the treatment of childhood asthma

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 885-892

  Harmanci, Koray ^a,b  

^a MINISTRY OF HEALTH   (Turkey)

^b Sancak Mahallesi   (Turkey)

Author keywords

Asthma; Children; Efficacy; Montelukast

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; PHOSPHOLIPASE A2; PLACEBO; PRANLUKAST; PROSTAGLANDIN SYNTHASE; SALMETEROL; THEOPHYLLINE; THROMBOXANE A2; ZAFIRLUKAST;

ABDOMINAL PAIN; ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ASTHMA; BRONCHOSPASM; CHILDHOOD DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TOLERABILITY; EAR INFECTION; FOOD; FOOD DRUG INTERACTION; HUMAN; LOW DRUG DOSE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MONOTHERAPY; NAUSEA; PATHOPHYSIOLOGY; PHARYNGITIS; PREDICTION; REVIEW; SINGLE DRUG DOSE;

EID: 36448949475     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Anderson SD. 2004. Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. Treat Respir Med, 3:365-79.
2. Altman LC, Munk Z, Seltzer J. 1998. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol, 102:50-6.
3. Becker A, Swern A, Tozzi CA, et al. 2004. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin, 20:1651-9.
4. Bisgaard H. 2001. Leukotriene modifiers in pediatric asthma management. Pediatrics, 107:381-90.
5. Bisgaard H, Loland L, Oj JA. 1999. No in exhaled air asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med, 160:1227-31.
6. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. 2005. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med, 171:315-22.
7. British Thoracic Society. 2005. National Asthma Campaign, Royal College of Physicians of London in association with the General Practitioner in Asthma Group, et al. The British guidelines on asthma management revised edition, November.
8. Bjermer L, Bisgaard H, Bousquet J, et al. 2000. Montelukast or salineterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). Resp Med, 94: 612-21.
9. Bronsky EA, Kemp JP, Zhang J, et al. 1997. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther, 62:556-61.
10. Buchvald F, Bisgaard H. 2003. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs niontelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol, 91:309-13.
11. Carraro S, Corradi M, Zanconato S, et al. 2005. Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J Allergy Clin Immunol, 115:764-70.
12. Drazen JM, Israel E, O'Byrrne PM. 1999. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med, 340:197-206.
13. Ducharme FM. 2004. Inhaled corticosteroids versus leukotriene antagonists as first-line therapy for asthma: a systematic review of current evidence. Treat Respir Med, 3:399-405.
14. Ducharme FM, Di Salvio F. 2002. Antileukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev, (1): CD002314.
15. Edelman JM, Turpin JA, Bronsky EA, et al. 2000. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med, 132:97-104.
16. Fernandez MP, Rubai SG, Solis MS, et al. 2006. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr Pulmonol, 41:222-7.
17. Global Strategy for Asthma Management and Prevention. 2006. NIH Publication No 02-3659, issued January, 1995 (updated 2006). Management Segment (Chapter 7).
18. Hakim F, Vizlozni D, Adler A, et al. 2007. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest, 131:180-6.
19. Israel E, Fischer AR, Rosenberg MA. 1993. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis, 148:1447-51.
20. Jones TR, Labelle M, Belley M. 1995. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol, 73:191-201.
21. Knorr B, Franchi LM, Bisgaard H, et al. 2001a. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics, 108:E48.
22. Knorr B, Holland S, Schwartz J, et al 2001b. Clinical pharmacology of montelukast. Clin Exp Allergy Rev, 1,:254-61.
23. Knorr B, Larson P, Nguyen HH. 1999. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol, 39:786-93.
24. Knorr B, Matz J, Bernstein JA, et al. 1998. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA, 279:1181-6.
25. Mehta, NP. 2000. Montelukast in childhood asthma. Indian Pediatr, 37:12019.
26. Meyer KA, Arduino JM, Santanello NC, et al. 2003. Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J Allergy Clin Immunol, 111:757-62.
27. Miraglia DGM, Piacentini GL, Caposso M, et al. 2007. Formoterol, montelukast, and budesonide in asthmatic children: Effect on lung function and exhaled nitric oxide. Respir Med, Apr 4 (Epub ahead of print).
28. Montuschi P, Mondino C, Koch P, et al. 2006. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin Immunol, 118:347-53.
29. Ng D, Salvio F, Hicks G. 2004. Antileukotriene agents compared to inhaled coTticosteToids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev, (2):CD002314.
30. National Heart Lung and Blood Institute. 2002. NAEPP Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics.
31. Noonan MJ, Chervinsky P, Brandont M. 1998. Montelukast, a potent leukotriene receptor antagonist, causes dose related improvements in chronic asthma. Eur Respir J, 11:1232-9.
32. O'Byme PM, Israel E, Drazen JM. 1997. Antileukotrienes in the treatment of asthma. Ann Intern Med, 127:472-80.
33. Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, et al. 2006. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr Pulmonol, 41:222-7.
34. Pearlman DS, Ostrom NK, Bronsky EA, et al. 1999. The leukotriene D4 receptor antagonist zafirlukast attenuates exercise induced bronchoconstriction in children. J Pediatr, 134:273-9.
35. Ram FS, Cates CJ, Ducharme FM. 2005. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev, 25:CD003137.
36. Robertson CF, Price D, Henry R, et al. 2007 Short-course montelukast for intermittent asthma in children. Am J Respir Crit Care Med, 175:323-9.
37. Salvi SS, Krishna MT, Sampson AP, et al. 2001. The anti-inflammatory effects of leukotriene-modifying drugs and their in asthma. Chest, 119:1533-46.
38. Skoner D. 2001. Montelukast in 2- to 5-year-old children with asthma. Pediatr Pulmonol, 21 (Suppl):46-8.
39. Stelmach I, Grzelewski T, Stelmach W, et al. 2002. Effect of triamcitiolone acetonide, montelukast, nedocromil sodium, formoterol on eosinophil blood conts, ECP serum levels and clinical parameters in children with asthma. Pol Merkuriusz Lek, 12:208-13.
40. Stelmach I, Korzeniewska A, Smejda K, et al. 2004. Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis. Pneumonol Alergol Pol, 72:85-9.
41. Strauch E, Moske O, Thoma S, et al. 2003. A randomized controlled trial on the effect of inontelukast on sputum eosinophils cationic protein in children with corticosteroid-dependent asthma. Pediatr Res, 54:198-203.
42. Szefler SJ. 2005. Facing the challenges of childhood asthma: What changes are necessary? J Allergy Clin Immunol, 115:685-8
43. Thomas SD, Luttermoser GK, Dickerson KS. 2007. Leukotriene inhibitors in the treatment of allergy and asthma. Am Fam Physician, 75:65-70.
44. Turner CR, Breslow R, Conklyn MJ, et al. 1996. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. J Clin Inves, 97:381-7.
45. Warner OJ. 2001. The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood. Allergy, 56(Suppl 66):22-9.
46. Wenzel SE. 1998. Antileukotriene drugs in the management of asthma. JAMA, 280:2068-9.
47. Wright AL, Taussig LM. 1998. Lessons from long term cohort studies: childhood asthma. Eur Respir J, 27(Suppl):17S-22S.
48. Zeiger RS, Szefler SJ, Phillips BR, et al. 2006. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol, 117:45-52.